The Company summarized the progress it has made in the last quarter. The Company now has a filed and effective "universal" shelf registration for the sale of up to $40M of the Company's securities. This universal shelf registration is expected to remain effective for up to three years. The Company has finalized several new research and testing agreements which included Dr. Ken Rosenthal at the North East Ohio Universities College of Medicine (NEOUCOM) for oral and genital Herpes, the University of California at San Francisco (UCSF; with Dr. Cheryl Stoddart as the principal investigator) for HIV in vivo studies, and Dr. Eva Harris Laboratory at the University of California at Berkeley (UCB) for Dengue viruses. The Company expects to announce the results of certain studies, that are already in progress, as soon as possible.

"We believe that our strong shareholder equity and cash position should enable us to meet the listing standards of a National Stock Exchange," said Eugene Seymour, MD, MPH, CEO of the Company.

"We are now planning to speed up our drug development programs, towards filing certain pre-Investigational New Drug applications with the US FDA," said Anil R. Diwan, PhD, President of the Company, "The Company's universal shelf registration should enable us to access the additional financing, as needed, for accelerating our programs."

SOURCE NanoViricides, Inc.